The Neuraminidase Inhibitor Market is expected to register a CAGR of 5% from 2025 to 2031, with a market size expanding from US$ XX Million in 2024 to US$ XX Million by 2031.
The research report on the Neuraminidase Inhibitor Market is segmented by type into oral antivirals and intravenous antivirals. Applications analyzed include influenza treatment, H1N1 management, and COVID-19 antiviral therapies. End-users include pharmaceutical companies, hospitals, clinics, and healthcare providers. The regional analysis covers key markets such as North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The market evaluation is presented in US$ for all segmental analyses. This report explores the increasing use of neuraminidase inhibitors in influenza and viral respiratory infections, including emerging therapies and the global health response to new viral strains.
Purpose of the ReportThe report Neuraminidase Inhibitor Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Neuraminidase Inhibitor Market Segmentation
Indication- Influenza Virus A
- Influenza Virus B
- Zanamivir
- Oseltamivir
- Peramivir
- Laninamivir
- Parenteral
- Oral
- Hospital Pharmacy
- Retail Pharmacy
Strategic Insights
Neuraminidase Inhibitor Market Growth Drivers- Increasing Prevalence of Influenza and Respiratory Infections: The growing prevalence of influenza and other respiratory infections is one of the leading drivers fueling the demand for neuraminidase inhibitors. The global rise in flu cases during seasonal outbreaks increases the demand for effective antiviral treatments. The therapeutic management of influenza heavily depends on neuraminidase inhibitors like Oseltamivir because they shorten symptom duration and lessen illness severity. Market projections indicate strong growth for the global neuraminidase inhibitor market due to higher flu infection rates, particularly in regions with unstable climate conditions. The threat of future influenza pandemics as observed with H1N1 and seasonal flu strains drives increased demand for antiviral medications. Government agencies and public health authorities allocate significant resources to stockpile medications for flu outbreaks which results in increased market size. Researchers are directing more attention toward antiviral medications designed to combat newly emerging influenza virus strains as they evolve. The persistent increase in flu cases together with the urgent need for prompt treatment to prevent complications maintains the market growth for neuraminidase inhibitors. Market forecasts predict consistent growth in the upcoming years which positions neuraminidase inhibitors as vital elements in worldwide health defenses against respiratory viral diseases.
- Advancements in Drug Formulation and Delivery: The quick progress in neuraminidase inhibitor formulation and delivery methods drives market expansion. The effectiveness and convenience of antiviral treatments have seen substantial improvements over recent years. Patients benefit from faster drug absorption through oral versions like Oseltamivir and inhaled treatments like Zanamivir which simplify administration especially in outpatient care settings. The market reach has expanded to include emerging markets because of these advancements which coincide with the growth in healthcare access in these regions. Global healthcare system advancements will make neuraminidase inhibitors available and acceptable to larger patient populations through these innovations. Pharmaceutical companies who work on enhancing drug bioavailability will achieve stronger therapeutic results which will enable faster and more effective treatments. The market for neuraminidase inhibitors is projected to expand substantially because of these formulation advancements. Developing new combinations of neuraminidase inhibitors with other antiviral agents aims to boost treatment efficacy while reducing resistance which leads to market expansion. The market share of neuraminidase inhibitors will increase because continuous innovation leads to their wider usage and integration into global influenza treatment protocols. The market growth for treating viral respiratory diseases remains driven by increasing demands for better treatments while new drug generations prepare to join the market.
- Government Initiatives and Investments: The neuraminidase inhibitor market growth depends on worldwide government actions which include policy initiatives and investments to fight influenza outbreaks. During flu season governments accumulate stocks of antiviral medications to maintain adequate supplies in case of an influenza pandemic. The actions of governments to build up antiviral medication reserves lead to higher demand for neuraminidase inhibitors which results in market expansion. The top priority for public health agencies remains flu readiness which includes required distribution of antiviral drugs at times when infections reach their highest levels. Through global investments in healthcare infrastructure countries now have better capability to deliver treatments to wider populations thereby advancing market growth. The World Health Organization (WHO) along with other global health organizations have emphasized the necessity of antiviral medications for public health emergencies which resulted in additional research funding for neuraminidase inhibitors. The COVID-19 pandemic revealed the necessity of fast-acting antiviral treatments which resulted in more investments toward antiviral research and development. The sustained progress of neuraminidase inhibitor formulations and their global distribution depends on this funding. The market for neuraminidase inhibitors will see steady growth in size and market share because governments are maintaining their focus on public health preparedness which will keep these antiviral treatments as essential elements of worldwide influenza management strategies.
- Growth of Combination Therapies: The neuraminidase inhibitor market shows great potential in combination therapies as a future trend. The collaboration between researchers and pharmaceutical companies involves active research into the use of neuraminidase inhibitors combined with other antiviral medications to boost treatment effectiveness against influenza and reduce drug resistance. Combination drugs are developed to overcome single-agent treatment limitations by attacking multiple viral lifecycle phases and several viral strains. Market size and share of neuraminidase inhibitors will likely undergo significant changes due to combination therapies since these treatments provide broader protection and potential reductions in illness duration. Researchers explore dual-therapy approaches because drug resistance against single-agent antivirals continues to rise which could lead to longer-lasting therapeutic outcomes. Market growth will substantially increase when combination therapies receive approval and enter public circulation because they will attract new patient populations who had unsuccessful results with monotherapies. The use of combination therapies shows potential for treating patients with co-infections including influenza coupled with bacterial infections which could increase their market share. Innovations in treatment paradigms will propel ongoing advancement within the neuraminidase inhibitor market which will secure its position as a major antiviral treatment option for many years.
- Shift Towards Personalized Medicine: The future of the neuraminidase inhibitor market will be influenced by the movement toward personalized medicine. The future of healthcare looks toward personalized medical approaches where treatments will be customized according to genetic information along with patient lifestyle and medication response patterns. The development of personalized medicine may transform how neuraminidase inhibitors are prescribed and used. Healthcare professionals who tailor treatment plans to individual needs boost neuraminidase inhibitor efficiency and lessen adverse effects while enhancing therapeutic results for each patient. Through personalized medicine healthcare providers can pinpoint patients who will respond best to particular antiviral treatments which increases the effectiveness of neuraminidase inhibitors. Experts predict substantial growth in personalized medicine because genetic testing will become more widespread and accessible. The increasing availability of genetic data about flu viruses and patient responses to antiviral drugs will push the medical field toward individualized treatment plans which will boost the need for neuraminidase inhibitors. A transition toward personalized medicine will make the market for neuraminidase inhibitors more sustainable through increased drug adoption and market share expansion. The global shift of healthcare systems towards precision medicine makes personalized treatment approaches essential for expanding the neuraminidase inhibitor market because they will deliver better-targeted and more effective therapy choices.
- Emergence of Resistance to Existing Drugs: Neuraminidase inhibitors share with numerous antiviral drugs the increasing problem of drug resistance. The influenza viruses develop resistance mechanisms against present antiviral drugs such as neuraminidase inhibitors as time progresses. Resistant flu strains threaten current antiviral therapy effectiveness which requires pharmaceutical companies to persistently create new drug formulations. The trend will cause a need for advanced antiviral drugs which can counteract resistant flu viruses. Researchers are currently working on discovering new neuraminidase inhibitors and creating next-generation antiviral treatments that maintain effectiveness against resistant flu strains. The future of the neuraminidase inhibitor market will be determined by the need for drugs that can defeat resistance as predicted by market forecasts. The market will experience a surge in demand for advanced antivirals as resistant strains proliferate which will increase market share for innovative treatments. Increased research and development investment will follow as market growth expands because of sector advancements. Resistance remains a persistent challenge which necessitates the creation of a strong pipeline of new antiviral medications to keep neuraminidase inhibitors effective against influenza.
- Development of New Neuraminidase Inhibitors for Novel Strains: The constant appearance of new viral strains presents pharmaceutical companies with the chance to create next-generation neuraminidase inhibitors for these novel infections. Oseltamivir along with other neuraminidase inhibitors fights many influenza strains but the virus develops resistance through mutation over time. The emergence of resistant viral strains presents a significant chance for pharmaceutical companies to create new antiviral agents that can defeat resistance while offering wider protection. The development of new inhibitors can be accelerated by drug discovery innovations which include artificial intelligence and machine learning techniques for finding new molecules. The need for stronger treatments is expected to grow because flu strains keep changing and become more difficult to manage. The need for new neuraminidase inhibitors extends to drugs that can treat various flu strains, including those resistant to current medications. The market for neuraminidase inhibitors will grow larger and capture a bigger share because healthcare providers are looking for effective influenza treatments while new treatments emerge. The market stands to benefit from considerable growth through substantial returns that will come from introducing new products into healthcare systems.
- Combination Therapies: The neuraminidase inhibitor market stands to benefit from lucrative growth opportunities through combination therapies. When neuraminidase inhibitors are used together with different antiviral medications or additional substances they become more effective in treatment and help prevent resistance while producing better results for patients. Scientific teams investigate multiple drug combinations to overcome monotherapy restrictions while viral resistance emerges as a significant problem. Pharmaceutical companies can develop stronger treatment options for influenza and other viral infections by merging neuraminidase inhibitors with other antiviral medications like protease inhibitors and polymerase inhibitors. The market share of neuraminidase inhibitors will likely increase because combination therapies using these inhibitors gain more acceptance in clinical practice. Antiviral combination therapy market growth projections indicate substantial advancement which will create extensive opportunities for new product development and market entry. Combination treatments can make healthcare resources more effective while improving viral infection management and patient results. Healthcare systems seeking better long-term treatments for flu and viral infections will likely make combination therapies with neuraminidase inhibitors essential to antiviral treatment plans which will expand market size. Modern antiviral treatments will rely heavily on neuraminidase inhibitors due to their ability to provide powerful multi-faceted treatment options.
- Increase in Preventive Healthcare and Prophylactic Use: The neuraminidase inhibitor market can expand thanks to rising use of preventive healthcare strategies which now include prophylactic applications of neuraminidase inhibitors. Neuraminidase inhibitors currently serve as standard treatment for active flu cases but their preventive application for high-risk groups is now receiving increased focus. High-risk groups such as people with weakened immune systems alongside healthcare workers and others who have close interactions with infected patients could receive advantages from preventive neuraminidase inhibitor treatments. People who travel and those living in densely populated regions increasingly seek antiviral drugs to prevent infections. People are becoming more aware of early intervention benefits and prevention which leads to increased demand for these drugs as individuals together with healthcare providers pursue proactive health measures to prevent illness. Market size growth for neuraminidase inhibitors is expected to rise because prophylactic applications will increase demand in regions with high flu transmission and seasonal influenza vulnerability. Pharmaceutical companies ready to broaden their neuraminidase inhibitor options for proactive use as preventive healthcare grows worldwide. The emphasis on preventive health measures could expand the market share of neuraminidase inhibitors as global health policies focus on reducing seasonal flu impact through preventive strategies. As wellness and disease prevention become more important to society's health goals, the market for antiviral drugs will experience strong demand growth.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Neuraminidase Inhibitor Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Neuraminidase Inhibitor Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Neuraminidase Inhibitor Market is expected to register a CAGR of 5% from 2025-2031.
The major driving factors supporting the Neuraminidase Inhibitor Market growth are- Increasing Prevalence of Influenza and Respiratory Infections, Advancements in Drug Formulation and Delivery, and Government Initiatives and Investments.
Key Future Trends in the Neuraminidase Inhibitor Market are- Growth of Combination Therapies, Shift Towards Personalized Medicine, and Emergence of Resistance to Existing Drugs.
Key companies in the Neuraminidase Inhibitor Market are - Strides Consumer LLC, BioCryst Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd, NATCO Pharma Limited, Alvogen, Amneal Pharmaceuticals LLC, Macleods Pharmaceuticals Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Neuraminidase Inhibitor Market - By Indication
1.3.2 Neuraminidase Inhibitor Market - By Drug Type
1.3.3 Neuraminidase Inhibitor Market - By Route of Administration
1.3.4 Neuraminidase Inhibitor Market - By Distribution Channel
1.3.5 Neuraminidase Inhibitor Market - By Region
1.3.5.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. NEURAMINIDASE INHIBITOR MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. NEURAMINIDASE INHIBITOR MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. NEURAMINIDASE INHIBITOR MARKET - GLOBAL MARKET ANALYSIS
6.1. NEURAMINIDASE INHIBITOR - GLOBAL MARKET OVERVIEW
6.2. NEURAMINIDASE INHIBITOR - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. NEURAMINIDASE INHIBITOR MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION
7.1. OVERVIEW
7.2. INDICATION MARKET FORECASTS AND ANALYSIS
7.3. INFLUENZA VIRUS A
7.3.1. Overview
7.3.2. Influenza Virus A Market Forecast and Analysis
7.4. INFLUENZA VIRUS B
7.4.1. Overview
7.4.2. Influenza Virus B Market Forecast and Analysis
7.5. OTHERS
7.5.1. Overview
7.5.2. Others Market Forecast and Analysis
8. NEURAMINIDASE INHIBITOR MARKET - REVENUE AND FORECASTS TO 2028 - DRUG TYPE
8.1. OVERVIEW
8.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
8.3. ZANAMIVIR
8.3.1. Overview
8.3.2. Zanamivir Market Forecast and Analysis
8.4. OSELTAMIVIR
8.4.1. Overview
8.4.2. Oseltamivir Market Forecast and Analysis
8.5. PERAMIVIR
8.5.1. Overview
8.5.2. Peramivir Market Forecast and Analysis
8.6. LANINAMIVIR
8.6.1. Overview
8.6.2. Laninamivir Market Forecast and Analysis
8.7. OTHER
8.7.1. Overview
8.7.2. Other Market Forecast and Analysis
9. NEURAMINIDASE INHIBITOR MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
9.1. OVERVIEW
9.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
9.3. PARENTERAL
9.3.1. Overview
9.3.2. Parenteral Market Forecast and Analysis
9.4. ORAL
9.4.1. Overview
9.4.2. Oral Market Forecast and Analysis
9.5. OTHERS
9.5.1. Overview
9.5.2. Others Market Forecast and Analysis
10. NEURAMINIDASE INHIBITOR MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
10.1. OVERVIEW
10.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
10.3. HOSPITAL PHARMACY
10.3.1. Overview
10.3.2. Hospital Pharmacy Market Forecast and Analysis
10.4. RETAIL PHARMACY
10.4.1. Overview
10.4.2. Retail Pharmacy Market Forecast and Analysis
10.5. OTHERS
10.5.1. Overview
10.5.2. Others Market Forecast and Analysis
11. NEURAMINIDASE INHIBITOR MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America Neuraminidase Inhibitor Market Overview
11.1.2 North America Neuraminidase Inhibitor Market Forecasts and Analysis
11.1.3 North America Neuraminidase Inhibitor Market Forecasts and Analysis - By Indication
11.1.4 North America Neuraminidase Inhibitor Market Forecasts and Analysis - By Drug Type
11.1.5 North America Neuraminidase Inhibitor Market Forecasts and Analysis - By Route of Administration
11.1.6 North America Neuraminidase Inhibitor Market Forecasts and Analysis - By Distribution Channel
11.1.7 North America Neuraminidase Inhibitor Market Forecasts and Analysis - By Countries
11.1.7.1 United States Neuraminidase Inhibitor Market
11.1.7.1.1 United States Neuraminidase Inhibitor Market by Indication
11.1.7.1.2 United States Neuraminidase Inhibitor Market by Drug Type
11.1.7.1.3 United States Neuraminidase Inhibitor Market by Route of Administration
11.1.7.1.4 United States Neuraminidase Inhibitor Market by Distribution Channel
11.1.7.2 Canada Neuraminidase Inhibitor Market
11.1.7.2.1 Canada Neuraminidase Inhibitor Market by Indication
11.1.7.2.2 Canada Neuraminidase Inhibitor Market by Drug Type
11.1.7.2.3 Canada Neuraminidase Inhibitor Market by Route of Administration
11.1.7.2.4 Canada Neuraminidase Inhibitor Market by Distribution Channel
11.1.7.3 Mexico Neuraminidase Inhibitor Market
11.1.7.3.1 Mexico Neuraminidase Inhibitor Market by Indication
11.1.7.3.2 Mexico Neuraminidase Inhibitor Market by Drug Type
11.1.7.3.3 Mexico Neuraminidase Inhibitor Market by Route of Administration
11.1.7.3.4 Mexico Neuraminidase Inhibitor Market by Distribution Channel
11.2. EUROPE
11.2.1 Europe Neuraminidase Inhibitor Market Overview
11.2.2 Europe Neuraminidase Inhibitor Market Forecasts and Analysis
11.2.3 Europe Neuraminidase Inhibitor Market Forecasts and Analysis - By Indication
11.2.4 Europe Neuraminidase Inhibitor Market Forecasts and Analysis - By Drug Type
11.2.5 Europe Neuraminidase Inhibitor Market Forecasts and Analysis - By Route of Administration
11.2.6 Europe Neuraminidase Inhibitor Market Forecasts and Analysis - By Distribution Channel
11.2.7 Europe Neuraminidase Inhibitor Market Forecasts and Analysis - By Countries
11.2.7.1 Germany Neuraminidase Inhibitor Market
11.2.7.1.1 Germany Neuraminidase Inhibitor Market by Indication
11.2.7.1.2 Germany Neuraminidase Inhibitor Market by Drug Type
11.2.7.1.3 Germany Neuraminidase Inhibitor Market by Route of Administration
11.2.7.1.4 Germany Neuraminidase Inhibitor Market by Distribution Channel
11.2.7.2 France Neuraminidase Inhibitor Market
11.2.7.2.1 France Neuraminidase Inhibitor Market by Indication
11.2.7.2.2 France Neuraminidase Inhibitor Market by Drug Type
11.2.7.2.3 France Neuraminidase Inhibitor Market by Route of Administration
11.2.7.2.4 France Neuraminidase Inhibitor Market by Distribution Channel
11.2.7.3 Italy Neuraminidase Inhibitor Market
11.2.7.3.1 Italy Neuraminidase Inhibitor Market by Indication
11.2.7.3.2 Italy Neuraminidase Inhibitor Market by Drug Type
11.2.7.3.3 Italy Neuraminidase Inhibitor Market by Route of Administration
11.2.7.3.4 Italy Neuraminidase Inhibitor Market by Distribution Channel
11.2.7.4 Spain Neuraminidase Inhibitor Market
11.2.7.4.1 Spain Neuraminidase Inhibitor Market by Indication
11.2.7.4.2 Spain Neuraminidase Inhibitor Market by Drug Type
11.2.7.4.3 Spain Neuraminidase Inhibitor Market by Route of Administration
11.2.7.4.4 Spain Neuraminidase Inhibitor Market by Distribution Channel
11.2.7.5 United Kingdom Neuraminidase Inhibitor Market
11.2.7.5.1 United Kingdom Neuraminidase Inhibitor Market by Indication
11.2.7.5.2 United Kingdom Neuraminidase Inhibitor Market by Drug Type
11.2.7.5.3 United Kingdom Neuraminidase Inhibitor Market by Route of Administration
11.2.7.5.4 United Kingdom Neuraminidase Inhibitor Market by Distribution Channel
11.2.7.6 Rest of Europe Neuraminidase Inhibitor Market
11.2.7.6.1 Rest of Europe Neuraminidase Inhibitor Market by Indication
11.2.7.6.2 Rest of Europe Neuraminidase Inhibitor Market by Drug Type
11.2.7.6.3 Rest of Europe Neuraminidase Inhibitor Market by Route of Administration
11.2.7.6.4 Rest of Europe Neuraminidase Inhibitor Market by Distribution Channel
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific Neuraminidase Inhibitor Market Overview
11.3.2 Asia-Pacific Neuraminidase Inhibitor Market Forecasts and Analysis
11.3.3 Asia-Pacific Neuraminidase Inhibitor Market Forecasts and Analysis - By Indication
11.3.4 Asia-Pacific Neuraminidase Inhibitor Market Forecasts and Analysis - By Drug Type
11.3.5 Asia-Pacific Neuraminidase Inhibitor Market Forecasts and Analysis - By Route of Administration
11.3.6 Asia-Pacific Neuraminidase Inhibitor Market Forecasts and Analysis - By Distribution Channel
11.3.7 Asia-Pacific Neuraminidase Inhibitor Market Forecasts and Analysis - By Countries
11.3.7.1 Australia Neuraminidase Inhibitor Market
11.3.7.1.1 Australia Neuraminidase Inhibitor Market by Indication
11.3.7.1.2 Australia Neuraminidase Inhibitor Market by Drug Type
11.3.7.1.3 Australia Neuraminidase Inhibitor Market by Route of Administration
11.3.7.1.4 Australia Neuraminidase Inhibitor Market by Distribution Channel
11.3.7.2 China Neuraminidase Inhibitor Market
11.3.7.2.1 China Neuraminidase Inhibitor Market by Indication
11.3.7.2.2 China Neuraminidase Inhibitor Market by Drug Type
11.3.7.2.3 China Neuraminidase Inhibitor Market by Route of Administration
11.3.7.2.4 China Neuraminidase Inhibitor Market by Distribution Channel
11.3.7.3 India Neuraminidase Inhibitor Market
11.3.7.3.1 India Neuraminidase Inhibitor Market by Indication
11.3.7.3.2 India Neuraminidase Inhibitor Market by Drug Type
11.3.7.3.3 India Neuraminidase Inhibitor Market by Route of Administration
11.3.7.3.4 India Neuraminidase Inhibitor Market by Distribution Channel
11.3.7.4 Japan Neuraminidase Inhibitor Market
11.3.7.4.1 Japan Neuraminidase Inhibitor Market by Indication
11.3.7.4.2 Japan Neuraminidase Inhibitor Market by Drug Type
11.3.7.4.3 Japan Neuraminidase Inhibitor Market by Route of Administration
11.3.7.4.4 Japan Neuraminidase Inhibitor Market by Distribution Channel
11.3.7.5 South Korea Neuraminidase Inhibitor Market
11.3.7.5.1 South Korea Neuraminidase Inhibitor Market by Indication
11.3.7.5.2 South Korea Neuraminidase Inhibitor Market by Drug Type
11.3.7.5.3 South Korea Neuraminidase Inhibitor Market by Route of Administration
11.3.7.5.4 South Korea Neuraminidase Inhibitor Market by Distribution Channel
11.3.7.6 Rest of Asia-Pacific Neuraminidase Inhibitor Market
11.3.7.6.1 Rest of Asia-Pacific Neuraminidase Inhibitor Market by Indication
11.3.7.6.2 Rest of Asia-Pacific Neuraminidase Inhibitor Market by Drug Type
11.3.7.6.3 Rest of Asia-Pacific Neuraminidase Inhibitor Market by Route of Administration
11.3.7.6.4 Rest of Asia-Pacific Neuraminidase Inhibitor Market by Distribution Channel
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa Neuraminidase Inhibitor Market Overview
11.4.2 Middle East and Africa Neuraminidase Inhibitor Market Forecasts and Analysis
11.4.3 Middle East and Africa Neuraminidase Inhibitor Market Forecasts and Analysis - By Indication
11.4.4 Middle East and Africa Neuraminidase Inhibitor Market Forecasts and Analysis - By Drug Type
11.4.5 Middle East and Africa Neuraminidase Inhibitor Market Forecasts and Analysis - By Route of Administration
11.4.6 Middle East and Africa Neuraminidase Inhibitor Market Forecasts and Analysis - By Distribution Channel
11.4.7 Middle East and Africa Neuraminidase Inhibitor Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa Neuraminidase Inhibitor Market
11.4.7.1.1 South Africa Neuraminidase Inhibitor Market by Indication
11.4.7.1.2 South Africa Neuraminidase Inhibitor Market by Drug Type
11.4.7.1.3 South Africa Neuraminidase Inhibitor Market by Route of Administration
11.4.7.1.4 South Africa Neuraminidase Inhibitor Market by Distribution Channel
11.4.7.2 Saudi Arabia Neuraminidase Inhibitor Market
11.4.7.2.1 Saudi Arabia Neuraminidase Inhibitor Market by Indication
11.4.7.2.2 Saudi Arabia Neuraminidase Inhibitor Market by Drug Type
11.4.7.2.3 Saudi Arabia Neuraminidase Inhibitor Market by Route of Administration
11.4.7.2.4 Saudi Arabia Neuraminidase Inhibitor Market by Distribution Channel
11.4.7.3 U.A.E Neuraminidase Inhibitor Market
11.4.7.3.1 U.A.E Neuraminidase Inhibitor Market by Indication
11.4.7.3.2 U.A.E Neuraminidase Inhibitor Market by Drug Type
11.4.7.3.3 U.A.E Neuraminidase Inhibitor Market by Route of Administration
11.4.7.3.4 U.A.E Neuraminidase Inhibitor Market by Distribution Channel
11.4.7.4 Rest of Middle East and Africa Neuraminidase Inhibitor Market
11.4.7.4.1 Rest of Middle East and Africa Neuraminidase Inhibitor Market by Indication
11.4.7.4.2 Rest of Middle East and Africa Neuraminidase Inhibitor Market by Drug Type
11.4.7.4.3 Rest of Middle East and Africa Neuraminidase Inhibitor Market by Route of Administration
11.4.7.4.4 Rest of Middle East and Africa Neuraminidase Inhibitor Market by Distribution Channel
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America Neuraminidase Inhibitor Market Overview
11.5.2 South and Central America Neuraminidase Inhibitor Market Forecasts and Analysis
11.5.3 South and Central America Neuraminidase Inhibitor Market Forecasts and Analysis - By Indication
11.5.4 South and Central America Neuraminidase Inhibitor Market Forecasts and Analysis - By Drug Type
11.5.5 South and Central America Neuraminidase Inhibitor Market Forecasts and Analysis - By Route of Administration
11.5.6 South and Central America Neuraminidase Inhibitor Market Forecasts and Analysis - By Distribution Channel
11.5.7 South and Central America Neuraminidase Inhibitor Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil Neuraminidase Inhibitor Market
11.5.7.1.1 Brazil Neuraminidase Inhibitor Market by Indication
11.5.7.1.2 Brazil Neuraminidase Inhibitor Market by Drug Type
11.5.7.1.3 Brazil Neuraminidase Inhibitor Market by Route of Administration
11.5.7.1.4 Brazil Neuraminidase Inhibitor Market by Distribution Channel
11.5.7.2 Argentina Neuraminidase Inhibitor Market
11.5.7.2.1 Argentina Neuraminidase Inhibitor Market by Indication
11.5.7.2.2 Argentina Neuraminidase Inhibitor Market by Drug Type
11.5.7.2.3 Argentina Neuraminidase Inhibitor Market by Route of Administration
11.5.7.2.4 Argentina Neuraminidase Inhibitor Market by Distribution Channel
11.5.7.3 Rest of South and Central America Neuraminidase Inhibitor Market
11.5.7.3.1 Rest of South and Central America Neuraminidase Inhibitor Market by Indication
11.5.7.3.2 Rest of South and Central America Neuraminidase Inhibitor Market by Drug Type
11.5.7.3.3 Rest of South and Central America Neuraminidase Inhibitor Market by Route of Administration
11.5.7.3.4 Rest of South and Central America Neuraminidase Inhibitor Market by Distribution Channel
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. NEURAMINIDASE INHIBITOR MARKET, KEY COMPANY PROFILES
13.1. STRIDES CONSUMER LLC
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. BIOCRYST PHARMACEUTICALS, INC
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. TEVA PHARMACEUTICALS INDUSTRIES LTD
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. NATCO PHARMA LIMITED
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. ALVOGEN
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. AMNEAL PHARMACEUTICALS LLC
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. MACLEODS PHARMACEUTICALS LTD
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. F. HOFFMANN-LA ROCHE LTD
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. GLAXOSMITHKLINE PLC
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. LUPIN
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1.Strides Consumer LLC
2.BioCryst Pharmaceuticals, Inc
3.Teva Pharmaceuticals Industries Ltd
4.NATCO Pharma Limited
5.Alvogen
6.Amneal Pharmaceuticals LLC
7.Macleods Pharmaceuticals Ltd
8.F. Hoffmann-La Roche Ltd
9.GlaxoSmithKline Plc
10.Lupin
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For